Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment Phase II clinical study expected to begin enrolling patients in H1 […]
Across BlueRock, we strive to hire the best talent. To do that, we take an open-minded approach to career trajectory and experience. Look a little closer and you will see a diverse workforce with employees who have transitioned from academia to industry, across industries, […]
I really love working in IT – I have an inherent need to solve problems and be a bit of a detective. Out of school I didn’t want to do IT. I loved computers but I thought doing it as a job would put […]
My name is Carlos Antonio Paladini. One of my early memories growing up in Lima, Peru and Sao Paulo, Brazil was reading about Che Guevara. Despite personally disagreeing with aspects of his philosophy, I remember being struck by a declassified CIA report describing Che […]
Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data on Parkinson’s disease impact on function of fifty study participants in BlueRock’s global non-interventional clinical study. Collaboration is part of BlueRock’s commitment to change the standard of care for treating Parkinson’s […]
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities Acceleration of the development of cell therapies in BlueRock’s pipeline, with initial focus on the ongoing BRT-DA01 clinical trial in Parkinson’s disease Berlin, June 8, 2022 – Bayer AG announced […]
Initiation of global non-interventional study for patients with Parkinson’s planned for the second half of 2022 as next step CAMBRIDGE, Mass., May 31, 2022 – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the completion of enrollment of its Phase […]
CAMBRIDGE, Mass., January 18, 2022 – BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived […]
CAMBRIDGE, Mass., January 6, 2022 – BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s […]
CAMBRIDGE, Mass., July 26, 2021 — BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth […]
